LL-37 (Cathelicidin) vs Palmitoyl Tripeptide-1
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →Palmitoyl Tripeptide-1
Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide that stimulates collagen production. It's one of two peptides in the Matrixyl 3000 complex, working synergistically with Palmitoyl Tetrapeptide-7.
Full details →Side-by-Side Comparison
| Aspect | LL-37 (Cathelicidin) | Palmitoyl Tripeptide-1 |
|---|---|---|
| Mechanism | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. | Mimics the skin's own mechanism for producing collagen by acting as a messenger peptide that signals fibroblasts to produce more collagen and other extracellular matrix components. |
| Typical Dosage | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. | Topical: Typically 2-4% in serums, often combined with Palmitoyl Tetrapeptide-7 as Matrixyl 3000. |
| Administration | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. | Topical application 1-2 times daily. The palmitoyl group enhances skin penetration compared to non-lipidated versions. |
| Side Effects | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. | Very well-tolerated. Suitable for most skin types including sensitive skin. |
| Best For |